Nuclear Y-box-binding protein-1 is a poor prognostic marker and related to epidermal growth factor receptor in uterine cervical cancer.
OBJECTIVE
Y-box binding protein-1 (YB-1) is a member of the cold shock protein family and functions in transcription and translation. Many studies indicate that YB-1 is strongly expressed in tumor cells and is considered a marker of tumor aggressiveness and clinical prognosis. Overexpression of epidermal growth factor receptor (EGFR) has been associated with poor outcomes in cervical cancer. Clinical trials of EGFR family-base therapy are currently being initiated in cervical cancer. Nuclear YB-1 expression correlates with EGFR expression in various types of cancer. However, the clinical significance of nuclear YB-1 expression in different settings, the correlation with EGFR, and the prognostic implications of YB-1 expression in cervical cancer remain elusive.


METHODS
Nuclear YB-1 expression was immunohistochemically analyzed in tissue specimens obtained from 204 patients with cervical cancer who underwent surgery. Associations of nuclear YB-1 expression with clinicopathological factors such as survival, EGFR expression, and human epidermal growth factor receptor 2 (HER2) expression were investigated.


RESULTS
Nuclear YB-1 expression was found in 41 (20.2%) of 204 cases of cervical cancer and correlated with disease stage, tumor diameter, stromal invasion, and lymph-node metastasis. Nuclear YB-1 expression also correlated with EGFR expression (P=0.0114) as well as HER2 expression (P=0.0053). Kaplan-Meier survival analysis showed that nuclear YB-1 expression was significantly associated with poor progression-free survival (P=0.0033) and overall survival (P=0.0003), respectively.


CONCLUSIONS
Nuclear YB-1 expression is a prognostic marker and correlates with EGFR expression in cervical cancer.
Department of Obstetrics and Gynecology, Kurume University School of Medicine, Asahi-machi 67, Kurume, Fukuoka, Japan. Electronic address: shinshin@med.kurume-u.ac.jp.
Shin
S
Nishio
Department of Obstetrics and Gynecology, Kurume University School of Medicine, Asahi-machi 67, Kurume, Fukuoka, Japan.
Kimio
K
Ushijima
Department of Pathology, Kurume University Hospital, Asahi-machi 67, Kurume, Fukuoka 830-0011, Japan.
Tomohiko
T
Yamaguchi
Department of Pathology and Laboratories, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan.
Yuko
Y
Sasajima
Department of Pathology and Laboratories, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan.
Hitoshi
H
Tsuda
Department of Gynecologic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan.
Takahiro
T
Kasamatsu
Department of Pathology, Kurume University Hospital, Asahi-machi 67, Kurume, Fukuoka 830-0011, Japan.
Masayoshi
M
Kage
Department of Pharmaceutical Oncology, Graduates School of Pharmaceutical Sciences, Kyushu University, Maedashi 3-5-1, Higashi-ku, Fukuoka 812-8582, Japan.
Mayumi
M
Ono
Laboratory of Molecular Cancer Biology, Department of Clinical Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kyushu University, Maedashi 3-5-1, Higashi-ku, Fukuoka 812-8582, Japan.
Michihiko
M
Kuwano
Department of Obstetrics and Gynecology, Kurume University School of Medicine, Asahi-machi 67, Kurume, Fukuoka, Japan.
Toshiharu
T
Kamura
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000096:biosynthesis*; D018572:Disease-Free Survival; D066246:ErbB Receptors / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D007044:Hysterectomy; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008197:Lymph Node Excision; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis; D002583:Uterine Cervical Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D051840:Y-Box-Binding Protein 1 / Q000096:biosynthesis*; D055815:Young Adult
D014408:Biomarkers, Tumor; D066246:ErbB Receptors; D018719:Erb-b2 Receptor Tyrosine Kinases; D051840:Y-Box-Binding Protein 1; C070856:YBX1 protein, human
Cervical cancer; EGFR; YB-1